Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: A 2-year study

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate if there is a correlation between some new emerging biomarkers, such as lipoprotein(a) (Lp[a]), apo(a) isoform phenotyping, soluble advanced glycation end products (sRAGE), soluble CD40 ligand (sCD40L), serum myeloperoxidase (MPO), and cardiovascular risk stratification. Research design and methods: Three hundred patients were enrolled in this open-label, casecontrol design trial: 156 hypertensive patients and 144 healthy subjects as control group. Hypertensive patients were treated according to the latest ESH/ESC guidelines, until the desirable goal of systolic blood pressure (SBP)

Original languageEnglish
Pages (from-to)1435-1445
Number of pages11
JournalCurrent Medical Research and Opinion
Volume28
Issue number9
DOIs
Publication statusPublished - Sep 2012

Keywords

  • Cardiovascular risk
  • Hypertension
  • Lipoprotein(a)
  • Non-conventional biomarkers
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: A 2-year study'. Together they form a unique fingerprint.

  • Cite this